Pain and empathy: GSK migraine simulator for Excedrin wins creative and consumer praise

Excedrin Migraine Experience

Seeing is believing in GlaxoSmithKlines’s latest campaign for Excedrin Migraine. Using a virtual reality simulator and working with migraine sufferers, GSK and ad agency DDB Remedy recreated what migraines "feel" like.

While pain is not included, of course, the experience does simulate the difficult visual symptoms that often signal the beginning of migraines such as disorientation, auras and sensitivity to light. 

In the TV ad, one mother who wears the headset and experiences what her daughter Elisabeth goes through breaks down, saying “I’m so sorry that you go through this.” Three other migraine sufferers and their loved ones or coworkers have similar experiences, which are posted as online videos at the Excedrin migraine experience website.

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

The campaign, which took about a year to create, bowed in April and recently snagged three creative awards at the Cannes Lions Health show. It’s also been generating substantial online attention with almost 19 million views, and more than 11 million of those on Facebook. The work has garnered more than 285,000 social engagements, which includes comments, retweets, likes and shares. Newly added to the marketing mix is a just-launched app that works with virtual reality viewers like Google Cardboard to create a three-dimensional version of symptoms.

Although the campaign is based around virtual reality, the goal of the work is to induce empathy for sufferers, not celebrate whiz-bang technology, said Amardeep Kahlon, GSK Consumer Healthcare marketing director for respiratory health, pain relief and skin care.

“The whole idea we kept in mind while creating the work was that there are 36 million people in the U.S. who suffer from migraines and the one thing they find in common is how very debilitating it is and how difficult it is to explain that to their partners and others around them,” he said.

Social media comments about the campaign reveal those similar themes of lifelong pain and even disbelief from people around them. One commenter on Facebook wrote, “For those who suffer from migraines, this commercial says it all. If you don't have them, watch it for someone who does. The only thing missing is the extreme pain that can come along with one. … My daughter has had them since she was 11. The first time she got one I took her to the emergency room. The doctor took me aside and said she was faking. Really.”

Kahlon added, "One of the best things about this has been watching online conversations. … Migraine sufferers finally feel that people understand them and what their experience is."

Virtual reality is an emerging technology for healthcare and pharma, but, as evidenced by several panels on the topic at Cannes, is growing in popularity as a way for marketers to better understand and communicate patient conditions and experiences.

- see the website
- watch the ad

Related Articles:
Top Cannes award goes to Philips, but Pfizer and Teva take home honors
New Health Lions prizes give pharma more chances to walk the Cannes red carpet
With latest hires, Klick sees sign of more creative times in pharma marketing
Glaxo OTC chief: When it comes to consumer health, pharma has the edge


Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.